ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
94.76
-0.85 (-0.89%)
Oct 16, 2025, 11:47 AM EDT - Market open
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.05M EUR in the quarter ending June 30, 2025, a decrease of -81.34%. This brings the company's revenue in the last twelve months to 6.02M, down -33.90% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
6.02M EUR
Revenue Growth
-33.90%
P/S Ratio
1,029.14
Revenue / Employee
87,290 EUR
Employees
69
Market Cap
7.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ABVX News
- 2 days ago - Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster - Seeking Alpha
- 9 days ago - ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 10 days ago - Why Is Abivax Stock Trading Higher On Monday? - Benzinga
- 11 days ago - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewsWire
- 16 days ago - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 22 days ago - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 4 weeks ago - Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - GlobeNewsWire
- 5 weeks ago - Abivax Presents First Half 2025 Financial Results - GlobeNewsWire